Pfizer faces new pressure to help world's poor
In this article Sarah Boseley and Nils Pratley describe how critics are asking increasingly urgent questions about Pfizer's attitude to those who need medicines in poor countries, saying that the company should take a lead in conceding a system of low prices in the developing world.
Critics also warn that the battle for drugs is no longer limited to AIDS, malaria, tuberculosis and similar infectious pandemics. Before long, the struggle will inevitably move on to the insidious and profitable diseases that affect millions in rich countries as well as poor, such as cancer.
Link to full Guardian article